Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Myriad Genetics, |
RCV003337414 | SCV004044765 | pathogenic | Familial adenomatous polyposis 1 | 2023-05-02 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
Ambry Genetics | RCV004067537 | SCV005016860 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-09-29 | criteria provided, single submitter | clinical testing | The p.E538* pathogenic mutation (also known as c.1612G>T), located in coding exon 12 of the APC gene, results from a G to T substitution at nucleotide position 1612. This changes the amino acid from a glutamic acid to a stop codon within coding exon 12. This alteration has been observed in at least one individual with a personal and/or family history that is consistent with APC-related disease (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Laboratory for Genotyping Development, |
RCV003164556 | SCV002758047 | pathogenic | Gastric cancer | 2021-07-01 | no assertion criteria provided | research |